Intellia Therapeutics Inc NTLA is trading significantly higher Thursday after the company announced its second-quarter financial results and said it plans to initiate Phase 1 trials for its next two candidates later this year.
Intellia Therapeutics reported a quarterly earnings loss of $1.01 per share, which came in below the estimate for a loss of 63 cents per share. The company reported quarterly revenue of $6.55 million, which came in below the estimate of $11.89 million.
Intellia Therapeutics said it plans to initiate first-in-human studies for both NTLA-2002 for hereditary angioedema and NTLA-5001 for acute myeloid leukemia in 2021.
"We look forward to initiating Phase 1 trials this year for our next two candidates, NTLA-2002 for HAE and NTLA-5001 for AML. We will also share additional interim data from NTLA-2001 later this year," said John Leonard, president and CEO of Intellia Therapeutics.
Price Action: Intellia Therapeutics has traded as high as $202.73 and as low as $16.54 over a 52-week period.
At last check Thursday, the stock was up 17.50% at $172.65.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
